메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

株式会社豊田自動織機に関するエリオットの声明

ロンドン, 2026年1月15日 -- Elliott Investment Management, L.P.およびElliott Advisors (UK) Limited（以下「エリオット」または「当社」）は、株式会社豊田自動織機（以下「豊田自動織機」または「同社」）の株式を相当額保有する大株主であるファンドに助言を行っております。当社は当該ファンドを代表し、以下の声明を本日付で公開しました。公開買付価格が一株あたり18,800円に変更されたことは、当初の公開買付価格が不十分であったことを認めるものではありますが、新たな公開買付価格は依然として豊田自動織機の価値を極めて大幅に過小評価しています。豊田自動織機は、市場を牽引する質の高い事業に加え、価値の高い金融資産を保有しており、エリオットは、これらを総合すると同社には一株あたり25,000円超の価値があると分析しています。かかる評価額は、2025年6月以降、トヨタ自動車その他のトヨタグループ各社に対する同社の持分の価値が約40％上昇したことや同社の主要な類似企業の評価が向上したことを反映し、一株あたり5,000円超増加しています。エリオットは、変更後の公開買付価格が少数株主の利益に資するものではないことから、本公開買付けに反対いたします。エリオットは、現行の取引条
- 황정호 기자
- 2026-01-15 15:00
Shoucheng Holdings (0697.HK): Foreign Investors Accumulate at Valuation Lows as Robotics Strategy Gains Market Recognition

HONG KONG, Jan. 15, 2026 -- Recently, Shoucheng Holdings (0697.HK) has experienced a notable shift in its capital market shareholder structure. According to disclosures from the Hong Kong Stock Exchange and transaction data from multiple financial terminals, foreign institutional investors have significantly increased their shareholdings while the Company's share price traded within a relatively low range, forming a clear pattern of sustained accumulation. According to the Company Secretary, certain foreign institutions have established positions at an average cost of approximately HK$2.08 pe
- 황정호 기자
- 2026-01-15 14:38
Open and Inclusive, Haikou Accelerates Its Rise as an International Performing Arts Capital

HAIKOU, China, Jan. 14, 2026 -- A news report from Haikou Municipal Bureau of Tourism, Culture, Radio, Television and Sports: Recently, the "Haikou on Stage, Dancing with the World" International Performing Arts Capital Promotion Conference was successfully held in Haikou. Centered on the theme "Culture Empowering Cities, Art Illuminating the Future," the event combined immersive audiovisual experiences with in-depth industry dialogue, bringing together leading professionals from China's performing arts sector and representatives from 34 major performance organizat
- 김장윤(JASON KIM) 기자
- 2026-01-15 13:40
Open and Inclusive, Haikou Accelerates Its Rise as an International Performing Arts Capital

HAIKOU, China, Jan. 14, 2026 -- A report from Haikou Municipal Bureau of Tourism, Culture, Radio, Television and Sports: Recently, the "Haikou on Stage, Dancing with the World" International Performing Arts Capital Promotion Conference was successfully held in Haikou. Centered on the theme "Culture Empowering Cities, Art Illuminating the Future," the event combined immersive audiovisual experiences with in-depth industry dialogue, bringing together leading professionals from China's performing arts sector and representatives from 34 major performance organizations n
- 김장윤(JASON KIM) 기자
- 2026-01-15 13:40
AI Can Unlock $4.5 Trillion in U.S. Labor Productivity Today, Reveals Cognizant's Latest "New Work, New World 2026" Report

[ 메디채널 황정호 기자 ] Cognizant's study shows AI is accelerating faster than projected, with 93% of jobs potentially affected today Findings also point to the limits of AI's impact, with skilling and human judgment playing a critical role in how organizations capture AI's full value TEANECK, N.J., Jan. 15, 2026 -- Cognizant today announced the release of "New Work, New World 2026," providing fresh analysis on how artificial intelligence (AI) will impact work and jobs. Building on the original report's release in 2024, the new research reveals AI is changing the workforce
- 황정호 기자
- 2026-01-15 13:01
Docquity Launches Engage™, an AI and Insights-Powered HCP Intelligence Engine for the Life Sciences Industry

SINGAPORE, Jan. 15, 2026 -- Docquity, a leading health tech company in Asia, today announced the launch of Docquity Engage™, an AI and Insights-powered market intelligence engine designed to help life sciences companies better understand and optimize engagements with healthcare professional (HCP) audiences. Backed by real-world insights from Docquity's network of more than 500,000 verified doctors across Asia, Docquity Engage™ provides pharmaceutical brand and field teams with real-time visibility into HCP behaviors and preferences, supported by AI-assisted recommendations to enable mo
- 김갑성 기자
- 2026-01-15 13:00
Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience

SINGAPORE, Jan. 15, 2026 -- Today, Visa, a world leader in digital payments, announced its support for Chinese Visa cardholders to pay with Apple Pay. Together with Apple, Visa will enable Chinese cardholders to add Visa cards[1] from participating banks to Apple Pay and make payments at overseas Visa-accepting merchants, in-store, in-app and online. Today, 79 percent[2] of in-person transactions globally are made contactlessly with NFC. Yin Xiaolong, General Manager at Visa Mainland China, said: "As global digital payments develop rapidly, consumers increasi
- 황정호 기자
- 2026-01-15 13:00
"The Insiders Forum" by Travellive Media Group: Trends Shaping Tourism Strategy

HANOI, Vietnam, Jan. 15, 2026 -- As Vietnam's tourism sector enters a post-pandemic restructuring phase, trends with the potential to generate long-term value are increasingly taking centre stage in the industry's development strategies. Against this backdrop, The Insiders Forum - a deep-dive seminar series within the HOTLIST Travellive Editor's Pick initiative organised by Travellive Media Group has been established as a professional dialogue platform to examine new growth drivers shaping Vietnam's tourism industry within a broader regional context. Within the 2025 theme "
- 황정호 기자
- 2026-01-15 12:31
Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease

SHANGHAI, Jan. 15, 2026 -- AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AB-1009, an investigational adeno-associated virus (AAV) gene therapy being developed for the treatment of late-onset Pompe disease. With this announcement, the AB-1009 program advances to Phase 1/2, and AskBio initiates a clinical trial in the United States to explore the safety of AB-1009. The company anticipates
- 김갑성 기자
- 2026-01-15 12:11
JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

[ 메디채널 김갑성 기자 ] Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients Complex modalities are WuXi Biologics' core growth engine, with 2/3 of the new integrated projects comprising bispecific/multispecific antibodies and ADCs Bispecific/multispecific antibodies are WuXi Biologics' most exciting, fastest‑growing and highest‑margin engine. With 196 projects in the pipeline, this modality contributes nearly 20% of t
- 김갑성 기자
- 2026-01-15 12:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-16_FRI

2026-01-15_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 16일 06시 00분